SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Shilpa Medicare gains on launching first branded generic anticancer drug ‘Dasashil'

24 Apr 2020 Evaluate
Shilpa Medicare is currently trading at Rs. 399.10, up by 4.55 points or 1.15% from its previous closing of Rs. 394.55 on the BSE.

The scrip opened at Rs. 381.15 and has touched a high and low of Rs. 405.00 and Rs. 381.15 respectively. So far 2272 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 538.75 on 26-Feb-2020 and a 52 week low of Rs. 190.80 on 04-Sep-2019.

Last one week high and low of the scrip stood at Rs. 429.55 and Rs. 371.25 respectively. The current market cap of the company is Rs. 3245.99 crore.

The promoters holding in the company stood at 53.80%, while Institutions and Non-Institutions held 26.89% and 19.31% respectively.

Shilpa Medicare has launched the Indian branded generic of Dasatinib, an anticancer drug with a brand name ‘Dasashil’. Dasashil is first branded generic anticancer drug with all dosage strength 20/ 50/ 70/ 100 mg tablets which is used for the treatment of Chronic Myeloid Leukaemia (CML). Current, monthly therapy cost of innovator is approximately 1.65 lakh, with the launch of Dasashil monthly cost of treatment will be reduced drastically to Rs 6440 as monthly therapy cost.

Dasahil will revolutionise the treatment by ensuring to make therapy available for more Indian patients due to increased affordability. The products are being manufactured and supplied from the state-of-the-art US Food and Drug Administration (US FDA) approved manufacturing facility.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare Share Price

411.55 0.30 (0.07%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×